Beck Bode LLC’s Allogene Therapeutics ALLO Stock Holding History

Beck Bode LLC’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-94,716	Closed	-$468K	–	136
2023 Q1	$468K	Buy	+94,716	New	+$607K	0.12%	120

Other funds holding ALLO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Beck Bode LLC's ALLO Position: Q2 2023 in Review

Beck Bode LLC sold out of Allogene Therapeutics (ALLO) in Q2 2023, closing a stake of 94,716 shares — an estimated $468K sold.

Beck Bode LLC first reported a position in ALLO in Q1 2023 and held it in 1 quarter. The position peaked at $468K in Q1 2023. 171 funds tracked by Wall St. Rank hold ALLO as of Q2 2023.

Beck Bode LLC reported no remaining Allogene Therapeutics position as of Q2 2023 after selling out during the quarter.
Beck Bode LLC sold 94,716 Allogene Therapeutics shares in Q2 2023, an estimated $468K.
Beck Bode LLC first reported a position in Allogene Therapeutics in Q1 2023 and held it in 1 quarter.
Beck Bode LLC's Allogene Therapeutics position peaked at $468K in Q1 2023.
171 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2023.

Based on Beck Bode LLC's 13F filing for Q2 2023, filed 10 Aug 2023.